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Abstract  
Introduction: In pediatric pharmacotherapy, many drugs are still used off-label, and their efficacy 
and safety is not well characterized. Different efficacy and safety profiles in children of varying ages 
may be anticipated, due to developmental changes occurring across pediatric life.  
Areas covered: Beside pharmacokinetic (PK) studies, pharmacodynamic (PD) studies are urgently 
needed. Validated PKPD models can be used to derive optimal dosing regimens for children of 
different ages, which can be evaluated in a prospective study before implementation in clinical 
practice. Strategies should be developed to ensure that formularies update their drug dosing 
guidelines regularly according to the most recent advances in research, allowing for clinicians to 
integrate these guidelines in daily practice.  
Expert Commentary: We anticipate a trend towards a systems-level approach in pediatric modeling 
to optimally use the information gained in pediatric trials. For this approach, properly designed 
clinical PKPD studies will remain the backbone of pediatric research.  
 
 
 
Keywords  
Pediatrics, clinical trial, off-label, maturation, PKPD, physiology, evidence-based dose 
recommendations, dose individualization, pharmacotherapy  
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1. Pharmacotherapy in clinical practice 
A major problem in pediatric healthcare is that drugs are largely used in an unlicensed or off-label 
manner (1). For many drugs, the pharmacokinetic, efficacy and safety profile in children is not very 
well characterized (2), resulting in a much lower level of evidence of drug efficacy and safety in 
pediatric pharmacotherapy compared to adult pharmacotherapy. This review focuses more on 
current drugs used in clinical practice, rather than how to bring new drugs to the pediatric market.  
 
In children, fewer and smaller studies on drug pharmacology are performed than in adults. This can 
be attributed to the ethical and practical limitations of pediatric trials (3, 4). As it is considered to be 
unethical to study drugs in healthy children, all pharmacological research in children involves 
diseased children of which the potential number of participants is limited while age may vary largely. 
Next, informed consent from the parents or legal guardians is needed and if children are old enough 
to understand, also informed assent is needed from the patients after informing them about the trial 
in such a manner they understand. Practical limitations of a trial include the limited number and 
volume of plasma samples that can be obtained per patient (e.g. the accepted rule that not more 
than 3% of circulating volume can be harvested during the course of the study), as well as the 
challenges related to obtain specimen at the extremes of childhood (e.g. extreme low birthweight 
infants). Furthermore, it is hard to find validated endpoints to measure efficacy in the pediatric 
population (5). Finally, both the dose that is used and sampling times are often limited to the 
patients’ need in clinical care, which may not be optimal from a research point of view.  
 
In absence of results of dedicated pediatric studies, pediatric doses have been scaled from adult 
pharmacokinetic (PK) and pharmacodynamic (PD) data using different methods (6, 7). These methods 
include empirical approaches (e.g. linear or allometric extrapolation on the basis of body weight or 
body surface area), or mechanistic modeling in which physiologically based pharmacokinetic (PBPK) 
models (8, 9) are used. Maturation functions that have been derived across the neonatal or pediatric 
age range, for instance for GFR in neonates(10) or for clearance in the youngest patients(11) , are 
largely data-driven and empirical. Mechanistic scaling methods have distinct advantages over 
empirical methods (12), however to date no single mechanistic method has been found suitable 
across the entire pediatric age range (13). Empirically determined dosages are typically expressed in 
mg/kg and have usually been adjusted based on clinical experience after which they are summarized 
in national formularies. It should be realized however, that this approach may not yield a dose with 
an optimal efficacy/safety profile, and that both during and after the process of optimizing a dose, 
the patients are at risk for over- and underdosing. 
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2. Developmental changes influencing drug pharmacology 
Inter-individual variability in pharmacokinetics (PK) and pharmacodynamics (PD) in the pediatric 
population is typically due to age and size, but can also for instance result from pharmacogenetic 
differences, disease or drug-drug interactions. Because developmental changes affect the 
pharmacology of administered compounds (14, 15), children who can vary in age between 0 and 18 
years of age are an even more heterogeneous population than adults. As such, in children altered PK 
and/or PD and toxicity due to exaggerated PD effects or off-target effects may be expected (16). This 
is especially relevant in the youngest age groups such as (prematurely born) neonates, as this is 
where the changes are the largest (17, 18).  
 
These developmental changes include maturation of enzyme expression activity influencing 
metabolic clearance of drugs, and age-related changes in glomerular filtration rate (GFR) and active 
tubular processes influencing renal excretion (19). Metabolizing enzymes such as P450 cytochromes 
(CYP) and UDP-glucuronosyltranferases (UGTs) may have different maturation profiles, as enzyme 
abundance increases or for some enzymes decreases with age (20, 21). Furthermore, depending on 
the drug properties, drug metabolism is also affected by hepatic blood flow and/or the unbound drug 
fraction (22), which also change throughout childhood. GFR is mostly influenced by renal blood flow 
(23) as has been described by many empirical formulas and models (24). Total renal clearance is also 
affected by passive and active transporters in the tubular epithelium. Moreover, the drug-protein 
binding to albumin and α1-acid glycoprotein increases with increasing age, due to an increase in 
protein expression and binding capacity. This results in an decreased unbound drug fraction (25, 26), 
although for most drugs changes in protein binding have no clinical consequence.  
 
In addition to the influence of age on elimination, age-related changes in body composition may also 
be of influence on the distribution of drugs. The body water to fat ratio is higher in neonates and 
young infants, as they have a larger amount of extracellular fluid and total-body water compared to 
adults (17). The exact implications of these changes for drug PK profiles are dependent on drug 
properties.  
 
For drugs that are taken orally, the absorption process may also be subject to changes. The 
absorption rate of most drugs is slower in neonates and young infants than in older children, due to 
delayed gastric emptying and lower intestinal motility (17). Especially in early life, gastric emptying is 
delayed compared to older children and adults, potentially delaying absorption in this population as 
well (27). Also, the gastric pH in neonates may be increased after oral feeding (28),which may affect 
the bioavailability of some drugs (15, 17). Furthermore, it is assumed that intestinal surface area and 
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age-associated blood flow in the intestinal mucosa is reduced in young infants (17). Unfortunately, 
developmental changes affecting drug absorption in infants and children have not been well-studied 
(17). 
 
Drug response can be increased or decreased during maturation and growth of a child due to 
developmental changes in expression and function of receptors and post-receptor mechanisms 
involved in drug action, or population specific pathophysiology. This requires dedicated studies to 
quantify the effects of these changes. Additionally, risk for drug toxicity in children can be increased 
or decreased due to PK and/or PD ontogeny and the efficacy-toxicity trade-off could be different in 
children (29).  
 
3. Developing evidence-based dosing regimens for children 
Due to anticipated drug dependent PK and PD changes among children of different ages and the 
current lack of knowledge on organ specific ontogeny processes (30), optimal drug efficacy and 
safety cannot be guaranteed when pediatric drug doses are derived from adult data (31). Instead, 
pediatric PKPD models should be developed in order to propose dosing regimens, across the 
pediatric population. In order to get to evidence-based dosing regimens for children, a multi-step 
approach (Figure 1) (32) has been proposed. This multi-step approach is based on the learning-
confirming principle (33) and it relies on the population approach (32).  
 
 
Figure 1. Proposed multistep approach for the optimization of drug dosing in children. The four steps 
that are proposed are [1] optimization of clinical trial designs based on simulations using preliminary 
data; [2] development and internal validation of population PKPD models using sparse data; [3] 
external validation of the population PKPD models using independent data; and [4] prospective 
clinical evaluation of the PKPD model-based dosing regimen. PK, pharmacokinetics; PD, 
pharmacodynamics. Printed with permission from Ince I et al. Drug Discovery Today 2009;14:316 – 20 
(32). 
 
Over the last decades, the population approach which is based on non-linear mixed effect modeling 
(34-36), has gained in popularity. Using this approach, models are developed to estimate population 
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PK and/or PD parameters in an entire population of patients simultaneously, while still taking into 
account that different observations come from different patients. This approach allows for the 
characterization of general trends in the population and also for differentiation between inter-
individual variability and residual or intra-individual variability within a single model (37). The latter is 
an advantage over the standard two-stage approach, in which first the PK or PD parameters are fit to 
observed data in each individual separately, requiring dense sampling, after which these individual 
parameters are presented using summary statistics like mean and standard error. Moreover, the 
population approach with its more statistically powerful description of inter-individual variability 
allows for a covariate analysis in which patient characteristics that can explain (part of) the inter-
individual variability can be identified (38). 
 
Particularly in children, the population approach as a tool in PK and/or PKPD analyses is preferred 
over the standard two-stage approach, because of limited sampling possibilities in individual 
children, known inter-individual variability that may or may not be related to age and advanced 
possibilities for so-called covariate analyses (39-41). This is particularly relevant for very young 
patients, such as term and preterm neonates, from whom only sparse samples can be collected. As a 
result, the population approach is the recommended approach by the EMA (42, 43) and FDA (44) for 
the analysis of pediatric PKPD data and the development of evidence-based dosing regimens. Finally, 
this approach is found to be superior over the standard-two stage approach (40) and also allows, 
when deemed appropriate, for the use of adult data as priors to lower the sample size needed 
and/or increase the statistical power of the study (45).  
 
The pharmacometric field develops mathematical models of physiology, pharmacology and/or 
disease to describe and quantify interactions between drugs and patients, including PK, PD and 
toxicity effects of both new and commonly used drugs. In pharmacometrics, most efforts have been 
focused on PK modeling, while in clinical care and drug development PK, PD and toxicity should be 
considered (42, 44, 46). As stated above, the concentration-effect relationship may change with age 
because of increased or decreased expression and function of receptors involved in drug action and 
response. For new drugs, the FDA and EMA developed a decision tree for the evaluation of the need 
for (the type of) pediatric trials (44, 47, 48). When it is reasonable to assume that children and adults 
have a similar disease progression and a similar response to intervention and it is also reasonable to 
assume similar concentration-response in both populations, then only PK studies to achieve plasma 
concentrations similar to adults and safety trials should be conducted. When only disease 
progression and response to intervention are assumed similar, PKPD studies to get concentration-
response information are necessary in addition to the previously mentioned PK and safety studies. 
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When disease progression and response to intervention are not assumed to be similar in pediatrics 
and adults, then both PK studies and safety/efficacy trials should be performed (48). For example, in 
infectious diseases, most model approaches are focused on development of a PK model to study PK 
maturation. These PK models are then used for simulations to give dose recommendations based on 
a target concentration pre-defined based on adult or in vitro data, rather than performing a PKPD 
trial (49).  
For some drugs with a low PK variability and/or when it is not possible to collect all required PK 
information, the dose can be also directly related to the PD with K-PD models (50) which can be, with 
extra caution, then used to inform dosing. However, when PKPD models can be identified, they 
should be preferred over K-PD models (51). Below we describe the different steps of figure 1 in order 
to get to evidence-based dosing guidelines in children.  
 
 
4. Study design and data collection 
Just as in any other research field, a proper study design is pivotal in answering the research 
questions of pharmacological studies. The study design should be such that the parameters in the 
anticipated model are identifiable. Because practice and theory often do not match, the design of a 
study should be discussed within a multidisciplinary team including clinicians, pharmacists, nurses 
and pharmacometricians. Commonly, inter- and intra-individual variability in PKPD is higher in 
children and especially in neonates compared to adults, which is due to maturation aspects and 
inter-individual differences in weight (52). Moreover, patients numbers are typically lower and as a 
result both these aspects should be accounted for in the study design as it causes the statistical 
power of analysis to decrease.  
 
4.1 Structural identifiability 
Structural identifiability is concerned with whether the parameters of a postulated model can be 
identified from a specified experiment or experiments with perfect input-output data (53). For 
instance, identifiability issues can arise when plasma metabolite concentrations are included in the 
model. Metabolite concentrations are mostly studied in special populations when the metabolite is 
suspected to be active or when a certain elimination pathway is being studied. Trial design can solve 
structural parameter identifiability issues by, for example, the use of different routes of 
administration or sampling of different media (e.g. blood and urine samples). For example, , without 
urine sampling upon a single dose over a long time interval to estimate the fraction of the dose that 
is metabolized through the involved pathway, identifiability issues in quantifying the metabolism and 
excretion pathways of the parent compound may occur. An example of this problem including how 
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to address this issue has been described elsewhere (54). In some cases, structural identifiability 
issues cannot be addressed by any method, which requires proper discussion of the specific 
limitations before starting the trial (54). 
 
4.2 Numerical identifiability 
Numerical identifiability relates to the informativeness of the data and can be improved by the 
optimization of study design and its execution (55). The impact of the study design on the precision 
and bias of the estimated parameters of a population model in adults is well established (56-60). In 
order to minimize the parameter uncertainty, two main clinical trial optimization methods exist, 
namely clinical trial simulation and optimal design (61). Clinical trial simulation allows for the 
investigation of a limited number of candidate study designs by simulating datasets with a given 
design and fitting the specified model to those simulated datasets. The mean and variance of the 
parameter estimates are then calculated, to come up with the bias and precision, respectively, of the 
design. Optimal design methods involve the direct calculation of the expected parameter standard 
errors, which could be compared to performing a clinical trial simulation with an infinite number of 
simulated datasets. Several optimal design software exists and most of these have been evaluated by 
Nyberg et al. (62). 
The optimization of all or specific PKPD parameters can be done over different clinical trial design 
parameters, like the number of samples, the number of patients included, the sampling times, the 
doses administered and patient characteristics (63, 64). The trial optimization can take into account 
practical and ethical (e.g. maximal number of samples per patients), as well as economic constraints 
(e.g. treatment costs). There is limited experience with all of these techniques in pediatric 
pharmacology research.  
 
4.2.1 Sampling 
Increased numbers of blood samples per patient will increase the accuracy and precision of the 
estimated model parameters and the estimated inter-individual and residual variability (56, 58, 59). 
Depending on the practical constraints, specific sampling times or sampling windows can be 
optimized. A design allowing for variation in sampling time (design with multiple sampling windows) 
and dosages among subjects can be beneficial and protect against the ill-effects of model 
misspecification, as has been demonstrated before (57). Despite the use of clinical trial simulations, 
practical constraints might prevent the identifiability of some model parameters. For example, the 
impossibility to sample at early times would prevent the estimation of the absorption rate.  
 
4.2.2 Data collection 
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When designing a PK(PD) study, information on patient characteristics (potential model covariates) 
that can correlate to PK or PD parameters need to be collected. Body weight and age are the most 
commonly used covariates in the pediatric population, to describe the influence of growth and 
development. For children younger than 2 years of age, gestational age, postmenstrual age, post-
conceptual age and postnatal age may be relevant covariates as well (65). Many other covariates 
which can influence the PK and /or PD of the drug studied, can be collected, such as disease state, co-
medications or the treatment with artificial devices such as extracorporeal membrane oxygenation 
(ECMO), ventricular assist devices or renal replacement (66, 67). In general, correlations between 
potential covariates should be avoided whenever possible, as the combination of two correlated 
covariates in a population model may result in bias in parameter estimates (68). 
 
4.2.3 Patient inclusion 
Several general design techniques allow to reduce bias, such as randomization and blinding. In 
general, potential confounders should be defined, such as co-treatment (e.g. inotropics in cardiac 
surgery patients), as they might bias the results of the analysis. The distribution of covariates likely to 
be included in the model should guide, whenever possible, patient inclusion in the trial (69) or trial 
arms, to prevent unbalanced designs hindering accuracy and precision (70). In a research protocol, it 
could be useful to identify strata to assure a spread in the covariate (e.g. age) values over the strata 
in order to gain information across the required range. When patients with only a limited range in 
covariate values are included, prediction to other patients outside this covariate range would require 
extrapolation. As interpolations are generally more reliable, the correlations of the covariates to PK 
or PD parameters can be extended to other subjects more reliably when the covariate values are 
spread and balanced.  
 
 
5. Population PKPD modeling and covariate analysis  
When the data are available for analysis, model development including a covariate analysis is 
performed to identify which factors can explain (part of) the observed inter-individual variability in 
the study. Possible covariates include demographic factors like age, body weight and gender or 
clinical factors like pharmacogenetics, disease state or comorbidities, or co-medication. In a data-
driven approach, covariate relationships are tested for their statistical significance and based on both 
statistical significance and possible clinical relevance they are retained in a model. Advantages of a 
data-driven approach in a covariate analysis, is that the covariate-parameter relationship is 
supported by the data. However, because it is a descriptive, empirical method, the extrapolation 
potential may be debatable. Mechanistic covariate models potentially have better extrapolation 
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potential as they are supported by scientific theories and in vitro and/or in vivo data (71). On the 
other hand, strong physiological and pharmacological evidence is yet needed for these approaches, 
confirmed by trial data and its PK(PD) model. Therefore, to date data-driven covariate analysis is 
considered the most achievable in most settings.  
 
Beside categorical influence of the covariates, the population approach also allows for continuous 
covariate functions to quantify maturation profiles in parameters across the pediatric age range. In 
order to develop a maturation function for e.g. drug clearance from for example 1-18 years of age, 
pediatric patients across this age range should be included. In general, when these maturation 
functions have been derived, it is typically not advised to extrapolate these functions to younger 
individuals < 1 year of age, including neonates, as extrapolations to neonates have almost never been 
successful (31). To make PK and/or PD predictions within this younger age range, these patients 
should also be included as these patients are not only difficult to predict, but they are also part of a 
very heterogeneous group with respect to body weight (almost tenfold difference) and age (0-30 
days of age) (10).  
 
In the pediatric population, body weight is often identified as the most statistical significant covariate 
on clearance and volume of distribution (65). When such a covariate-parameter relationship has 
been identified, one should realize that it describes the correlation between body weight and a PK 
parameter, which does not necessarily imply a causal relationship. Therefore caution is needed when 
extrapolating these models to subpopulations at the extremes of the age-adjusted body weight 
range, e.g. underfed or obese children. For example, Van Rongen et al. found that midazolam 
clearance in adolescent patients with overweight or obesity seemed not very different from 
literature values of adolescents with a healthy body mass index (72). While this implies that dosing in 
adolescents with obesity should not be expressed in mg/kg, in another example, i.e. busulfan, a 
weight-based algorithm proved to lead to predictable concentrations both in underweight and 
overweight individuals (73). Furthermore, even in pediatrics there are also special populations like 
patients with renal and/or hepatic impairment. Due to high variability in PK parameters during 
childhood and usually few available plasma samples per individual over a prolonged time interval, 
functional impairment may become apparent only after the growth spurt in adolescence, when 
significant decrease in GFR and/or increase in metabolic load can be measured (74). Therefore it can 
be hard to distinguish between functional impairment and maturation of clearance pathways in 
children. 
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6. Model validation 
When a trial is performed and a PKPD model has been developed, the model performance should be 
evaluated (75), which is a step that is often neglected (65). Marsot et al. have reviewed published 
population pharmacokinetic models developed in pediatric subjects from neonates to 2-year-old 
toddlers between 1985 and December 2010 (65). Disturbingly, the authors reported the use of model 
evaluation methods including bootstrap, cross-validation, Monte-Carlo simulations in only 37% of 
articles and the use of external validation methods in only 11% of articles. Without thorough model 
validation, predictions from simulations can however not be confirmed and therefore the level of 
certainty about the model-derived dosing recommendation is very low. Because it is essential to 
validate models if clinical decisions are being based on a model, there is obviously an urgent need for 
higher standards in the methodologies used to develop and publish pediatric pharmacological 
studies, with a need to systematically implement advanced model validation methods and external 
model validation.  
 
Validation techniques include goodness-of-fit plots (76), and simulation-based diagnostics by means 
of for instance visual predictive checks (VPC)(77, 78) or normalized prediction distribution errors 
(NPDE) (79). Furthermore, bootstrapping methods can be used to evaluate the precision of model 
predictions and to calculate imprecision in model parameter estimates (80). These validation and/or 
evaluation tools are available, however they may need adaptations for use in the pediatric 
population (75). For example, goodness-of-fit plots should be stratified for different age or weight 
categories, to check for misspecification in covariate-parameter correlations(75, 76).  
 
This internal validation should be followed by an external validation by applying the model to data 
from other studies, whenever available (75). This external validation is important to make sure that 
the model reflects the target population, instead of a model that only reflects the patients studied 
during model development. For example, morphine pharmacokinetics have been described by a PK 
model for morphine in children younger than 3 years of age (81) and this model has been externally 
evaluated with six other datasets from literature (82). Krekels et al. proved that the predictive 
performance of the morphine PK model was good in the external datasets of neonates and infants up 
to 1 year of age. It is important to consider which criteria are used in the model evaluation, as not all 
validation techniques allow to separate predictive models from models descriptive to one dataset 
only (75). The good predictive performance of a model is proven only once it has been both internally 
and externally validated. We emphasize that an external validation does not always require a new 
trial, as for commonly used drugs literature data may be available that can be used to evaluate the 
model’s performance. For new drugs, it might be beneficial to split the data and use one third of the 
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data to externally validate the model. This validated model can then be used for simulations to 
individualize drug regimens using a predefined therapeutic endpoint, e.g. an AUC/MIC < plasma 
concentration threshold or a PD endpoint like a sedation score. 
 
 
7. Prospective clinical trials for individualized dosing 
Validated models are not a goal in itself, but these models can be used to individualize drug regimen, 
using the covariates included in the model such as bodyweight, or gestational age (83). Before these 
dosing recommendations can be implemented in the clinic, a prospective clinical evaluation study 
should preferable be performed to ascertain that the desired endpoints are obtained using the novel 
dosing regimen (32). This prospective study should be seen as a first stage of implementation of the 
new dosing recommendations into clinical practice. So far in the period from 1985-2010, Marsot et 
al. found that only 48 out of 98 population PK studies concluded with dosing recommendations and 
none of these dosing recommendations were followed by a new study devoted to their clinical 
evaluation (65), which displays a need for tailoring of model-based dosing regimen, and their clinical 
evaluation. Wilbaux et al. describe in their review of pharmacometric models for primarily renally 
eliminated antibiotics in neonates, that despite many models and prospective trials for most of the 
reviewed antibiotics in children there is still no consensus on the optimal dosing regimen for most 
antibiotics (84). 
 
However, an example of a prospective study in which an individualized dosing regimen is evaluated 
that was proposed based on a previously developed model, is amikacin dosing in preterm and term 
neonates. In this study, scenario-based simulations were performed using the developed PK model 
that identified both body weight and the postnatal age of neonates as covariates. This amikacin 
neonatal PK model (85) was used to derive a novel amikacin dosing regimen in neonates that was 
prospectively studied (86). The results of the prospective study show that the measured plasma 
concentrations were accurately predicted by the model and using the model-based dose 
recommendations, 90.5% and 60.2% of the patients had optimized peak and trough concentrations 
respectively (86). In this case, correcting for PK was sufficient, as success of treatment is measured by 
concentration, probably because target concentrations and exposure are bacteria specific and not 
age-specific. 
 
In another example, Krekels et al. performed a study in which a model-based dosing regimen 
correcting for developmental difference in morphine PK (81), was prospectively evaluated in children 
receiving morphine after a surgery procedure (87). Their study revealed that the plasma 
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concentrations were as expected based on the model predictions, and confirmed that the PK model-
based dosing regimen improved the exposure and led to clinical improvements. Moreover, it 
revealed that PK does not account for all inter-individual variability and that there is a need for 
investigation in PD variability to further optimize the dosing guideline as older children proved less 
sensitive to morphine than neonates (87). 
 
The described model-based approach to guide dosing in children is mainly applied to small molecular 
drugs, but its value has also been proven for biologics. Thymoglobulin® is an anti-thymocyte globulin 
(ATG) that is used as serotherapy in patients undergoing hematopoietic cell transplantations (HTC). It 
is assumed that individualizing the ATG dosing to prevent graft-versus-host disease and rejection of 
transplants, will improve survival in pediatric HCT (88). Admiraal et al. described the 
pharmacokinetics of ATG in children and concluded after internal and external validation that the 
developed PK model was able to predict thymoglobulin concentrations in children correctly (88). 
Model-based simulations proved the current dosing regimens to be suboptimal leading to varying 
exposures between individuals, especially in patients with a baseline lymphocyte count that was 
lower than average and/or a body weight that was higher than average (88). To improve dosing, the 
relation between ATG exposure and clinical outcomes were studied and a PKPD model was 
developed to describe this relation (89). It was found that the exposure before transplantation of at 
least 40 AU×day/mL correlated with a decrease the incidence of graft-versus-host-disease and a 
lower incidence of graft failure (89). Using this model-based approach, quantification of these PKPD 
relation resulted in a dosing regimen to achieve the optimal exposure to improve efficacy and safety 
of ATG treatment in children undergoing transplantation (89), which is currently prospectively 
evaluated in clinical practice. 
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Expert commentary  
Over the past decades, the field of pharmacology has been evolving and modeling and simulation has 
started to play a role in improving pharmacotherapy in the pediatric population (7, 29). In general, 
more efforts should be put in the design of pediatric studies, so that the obtained data are the most 
informative to answer the research question. Furthermore, the data should always be analyzed with 
advanced statistical tools like population modeling to enable extraction of all this information and to 
perform proper covariate analyses. In addition, research efforts should focus on previously unstudied 
drugs, instead of performing new (PK) studies on drugs that have already been extensively studied in 
children, such as aminoglycosides in neonates on which many publications are yet available. For the 
latter, there would however still be much to gain in terms of translation of the results on the PK of 
these drugs into clinical practice (90) for instance by identifying subgroups for which these dosing 
guidelines may need further adaptation (e.g. neonates with asphyxia or renal insufficiency). 
However, before results of population models are used to guide dosing in clinical practice, it is 
imperative that these models are properly validated, both internally and externally, upon which the 
proposed model-based dosing regimen can be tested in a prospective trial. This next step, the 
translation of a model to novel dosing regimens, is often not taken (65), even though this is the most 
relevant step for improvement of pharmacotherapy in clinical care.  
 
While more PK and PD information can be extracted from a trial on a specific drug in a specific age 
population when the population approach is used (90), it is not realistic to perform a trial and 
develop and validate a PK or PKPD model for each drug in each pediatric population. Therefore, 
further steps towards generating more generalizable, system-specific, information are also needed. 
In this respect, it has been hypothesized that pediatric PK models with covariate functions describing 
the ontogeny of drug clearance may contain drug-specific and physiological system-specific 
information(91). For example, the earlier mentioned neonatal model for GFR, originally developed to 
describe amikacin PK (10), was successfully used to predict ontogeny of clearance of other drugs 
eliminated by GFR (85, 92). However, more research on this type of extrapolation is needed, as it was 
reported that also drug properties may affect covariate relationships. For hepatically cleared drugs, it 
was for instance found that similarity in extraction ratio between the model drug and the drug the 
covariate relationship is extrapolated to, is important (93).  
  
In addition, strategies should be developed to enable national formularies to adapt their dosing 
guidelines regularly based on the most recent advances in research published in literature, allowing 
clinicians to integrate guidelines in daily practice. For example, in gentamicin and tobramycin therapy 
in neonates, studies have shown that current dosing according to the Dutch National Formulary for 
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Children (94), the British National Formulary for Children (95), Neofax (96) and the Red Book (97) 
leads to suboptimal exposure and inadequate target concentrations in neonates (98). Therefore, 
guidelines and national formularies should adapt to the most recent insights resulting in personalized 
medicine and improved clinical care. This is the case for gentamicin dosing in neonates, for which the 
Dutch National Formulary for Children (94) recently adjusted the dosing in premature neonates with 
a post-natal age of 0-7 days based on available literature.  
 
 
Five-year view  
In the next years, we anticipate a stronger trend towards the generation and identification of more 
generalizable information from pediatric clinical trials that have been performed on specific drugs. 
The trend has already been initiated by increased focus on research fields like PBPK modeling and 
systems pharmacology. Both fields integrate information from multiple clinical and/or preclinical 
sources to derive drug-specific and system-specific information. Identifying developmental patterns 
in system-specific parameters can help to quantify and predict inter-individual variability in drug 
absorption and disposition, and receptor function and expression (99). The advantage of systems-
based approaches in quantifying and predicting drug PK has for instance been illustrated for another 
special patient population. In morbidly obese and bariatric surgery patients, oral and intravenous 
midazolam PK was described by a semi-physiological PK model (100), taking into account both gut 
wall and liver processes. In this model, system-specific parameters (e.g. hepatic blood flow) and 
drug-specific parameters (e.g. extraction ratio) were combined, leading to the conclusion that in 
morbidly obese patients, hepatic CYP3A activity is reduced in comparison to healthy volunteers but 
normalizes one year after weight loss surgery (100). This approach does not require as much 
information as a full PBPK or systems pharmacology model, which is not always experimentally 
deducible. As some system-specific information is lacking, e.g. liver blood flow in special populations 
(100), different scenarios for this physiological parameter were tested for their influence on the 
conclusion. Ultimately, methods combining the population approach, based on outcome data, and 
the systems approach are being developed. In the near future we will see more of this approach in 
pediatric patients as well.  
 
In order to describe the system and the maturation processes within the system, knowledge is 
required on disease mechanisms and drug action to be accounted for in the system models. 
Furthermore, to scale drug efficacy across a wide age range, the same endpoint to measure efficacy 
in children and adults is needed or scaling of endpoints between children and adults should be 
explored because PD endpoints used in adults cannot always be applied to children. For example, the 
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gold standard for pain assessment in adults is based on self-report and in especially young children 
the same method cannot be applied. Therefore other validated and well-established scales like the 
COMFORT-B for pain after major surgery (101, 102) and PIPP pain scores for procedural pain in 
preterm neonates (103) have been used in preverbal children. It is important to validate these scores 
before use in clinical practice (101, 103), because even these pain scores give variable information 
about pain (104). The lack of validated PD endpoints in children is one of the most important 
obstacles in the transition of mostly PK studies to the more clinical relevant PKPD studies. Often it is 
assumed that a certain drug exposure that is associated with desired drug action in adults will 
produce the same response in children (105). However, this assumption does not hold true in many 
cases and therefore biomarkers for disease and drug efficacy in the pediatric population are urgently 
needed to identify and quantify drug effects (105). To identify biomarkers for disease mechanisms 
and drug action in pediatrics, we foresee a trend in more interest in the metabolomics field (106, 
107). Validated biomarkers and clear endpoints could also prevent pediatric trials to fail in answering 
the question addressed in the trial (108).  
 
Predictive systems pharmacology models give novel insights in pediatric pharmacotherapy in relation 
to ontogeny and (patho)physiology, and advanced statistical techniques have been very instrumental 
in this field. As different types of data and multiple data analysis techniques are combined to 
integrate all information, pediatric pharmacological research will become even more 
multidisciplinary in nature. Not only in study design and data analysis, but also in implementation of 
novel dosing regimens in daily pharmacotherapy, professionals with different expertise are required 
to collaborate. There is an important urgency to actually use information that has been gathered on 
PK and/or PD of drugs in children into dosing recommendations through validated models and 
subsequent clinical trials. Ultimately all efforts should lead up to up-to-date formularies that can be 
used in clinical practice. To this end, approaches to accelerate the generation of dosing guidelines for 
drugs that have actually not yet been studied through PKPD modeling studies in children are needed 
for which physiologically based principles are promising. As such, in the next years, we anticipate a 
trend towards a systems-level approach in pediatric modeling to optimally use the information 
gained in pediatric trials. For this approach, properly designed clinical PKPD studies will remain the 
backbone of pediatric research. Ultimately, these efforts will lead to individualized drug treatment as 
standard pediatric care.  
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Key issues 
- In pediatric pharmacotherapy, many drugs are still used off-label, and their efficacy and 
safety is not well studied, even though developmental changes in children are known to lead 
to different pharmacokinetics (PK) and pharmacodynamics (PD) of drugs.  
- Even though multiple PK(PD) studies have been performed particularly for many commonly 
used drugs, information obtained in these trials are not automatically translated into dosing 
regimens for clinical care. 
- Proper study design can prevent structural and numerical identifiability of the PKPD model 
and clinical trial simulation and optimal design software provides a useful tool for optimizing 
the study design.  
- As opportunities for plasma sampling in individual children are limited, the population 
approach is the preferred approach in PK and/or PD analyses to extract the greatest amount 
of PKPD information from the clinical data and perform covariate analyses.  
- The optimal dosing regimen identified from a validated PKPD model should be preferably 
evaluated in a prospective clinical trial before implementation in clinical practice.  
- Strategies should be developed to ensure that formularies update drug dosing guidelines 
regularly according to the most recent advances in research.  
- More emphasis is needed to identify, quantify and validate biomarkers for disease and drug 
efficacy in the pediatric population. 
- During the next few years, we anticipate a shift towards a systems-level approach in pediatric 
modeling in pediatric trials. For this approach, population PKPD studies will remain the 
backbone of pediatric research.  
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Reference annotations  
** Of considerable interest 
- Admiraal, R., et al. (2014) Towards evidence-based dosing regimens in children on the basis 
of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child 99(3), 267-72 
Review on performing a population PKPD study and translating these results into evidence-
based dosing regimens 
 
- De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, et al. A 
neonatal amikacin covariate model can be used to predict ontogeny of other drugs 
eliminated through glomerular filtration in neonates. Pharmaceutical research. 
2014;31(3):754-67. 
Systems approach: a neonatal GFR model can be used to predict PK of multiple drugs 
 
- De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-
PD modelling in paediatric clinical research. European journal of clinical pharmacology. 
2011;67 Suppl 1:5-16. 
Overview on how modeling and simulation can help in pediatric clinical research 
 
- Kearns GL, Artman M. Functional Biomarkers: an Approach to Bridge Pharmacokinetics and 
Pharmacodynamics in Pediatric Clinical Trials. Curr Pharm Des. 2015;21(39):5636-42. 
Review on the need for biomarkers capable of measuring drug response in both a time and 
age dependent fashion 
 
- Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the 
descriptive and predictive performance of paediatric morphine population models. 
Pharmaceutical research. 2011;28(4):797-811. 
Overview of evaluation and validation techniques in children 
 
- Smits A, De Cock RF, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CA. Prospective 
Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in 
Clinical Practice. Antimicrob Agents Chemother. 2015;59(10):6344-51. 
Prime example of a prospective trial to evaluate a model-based dosing regimen  
 
- Valitalo PA, van den Anker JN, Allegaert K, de Cock RF, de Hoog M, Simons SH, et al. Novel 
model-based dosing guidelines for gentamicin and tobramycin in preterm and term 
D
ow
nl
oa
de
d 
by
 [E
ras
mu
s U
niv
ers
ity
] a
t 0
8:3
1 0
8 J
un
e 2
01
6 
 Page 19 
 
neonates. J Antimicrob Chemother. 2015;70(7):2074-7. 
Prime example of an evidence-based dosing regimen proposed after model development 
and validation  
 
- Zhao W, Biran V, Jacqz-Aigrain E. Amikacin maturation model as a marker of renal maturation 
to predict glomerular filtration rate and vancomycin clearance in neonates. Clin 
Pharmacokinet. 2013;52(12):1127-34. 
External validation where a neonatal GFR model is used to predict vancomycin PK 
 
* Of interest 
- Bellanti F, Della Pasqua O. Modelling and simulation as research tools in paediatric drug 
development. Eur J Clin Pharmacol. 2011;67 Suppl 1:75-86. 
Literature review that concludes that a consensus is lacking in how to assess the impact of 
developmental factors on efficacy and safety of pharmacotherapy in children 
 
- Joseph PD, Craig JC, Caldwell PH. Clinical trials in children. Br J Clin Pharmacol. 
2015;79(3):357-69. 
Recent review of challenges and solutions for performing clinical trials in children 
 
- Krekels EH, Tibboel D, de Wildt SN, Ceelie I, Dahan A, van Dijk M, et al. Evidence-based 
morphine dosing for postoperative neonates and infants. Clin Pharmacokinet. 
2014;53(6):553-63. 
Prime example of a prospective trial to evaluate a model-based dosing regimen 
 
- Krekels EH, DeJongh J, van Lingen RA, van der Marel CD, Choonara I, Lynn AM, et al. 
Predictive performance of a recently developed population pharmacokinetic model for 
morphine and its metabolites in new datasets of (preterm) neonates, infants and children. 
Clin Pharmacokinet. 2011;50(1):51-63. 
Prime example of an external model validation 
 
- Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr 
Pharmacol Ther. 2014;19(4):262-76. 
Physiological changes affecting pharmacokinetics in children  
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- Marsot A, Boulamery A, Bruguerolle B, Simon N. Population pharmacokinetic analysis during 
the first 2 years of life: an overview. Clin Pharmacokinet. 2012;51(12):787-98. 
Overview of PK analysis with proper validation, prospective trials and development of 
dosing regimens 
 
- Thomson AH, Elliott HL. Designing simple PK-PD studies in children. Paediatr Anaesth. 
2011;21(3):190-6. 
Review on how to design efficacy trials in children for population PKPD analysis 
 
- van Dijk M, Ceelie I, Tibboel D. Endpoints in pediatric pain studies. Eur J Clin Pharmacol. 
2011;67 Suppl 1:61-6. 
Clear illustration of the lack of pharmacodynamic data in pain studies in children 
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